APOB and metabolic syndrome: Patients with MetS were significantly less likely to attain their LDL-C (27 vs. 37 %; P < 0.001), non HDL-C (35 vs. 55 %; P < 0.001) and apo B (35 vs. 54 %; P < 0.001) targets compared to patients without MetS.